Company Overview

Vivos Therapeutics, Inc. is a U.S.-based medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related sleep-disordered breathing conditions. The company operates at the intersection of healthcare services, medical devices, and dental sleep medicine, providing non-invasive oral appliance therapies intended as alternatives or complements to traditional CPAP treatment. Its core offerings are marketed primarily through trained dental and medical professionals rather than direct-to-consumer channels.

The company was founded in 2016 and has positioned itself around a proprietary, multidisciplinary treatment approach known as the Vivos CARE protocol, which integrates oral appliances, medical oversight, and patient monitoring. Vivos Therapeutics became a publicly traded company in 2020 through a reverse merger and trades on the NASDAQ under the ticker VVOS. Its strategy has evolved from a device-centric model to a broader healthcare platform combining devices, clinical services, and practice support infrastructure.

Business Operations

Vivos Therapeutics generates revenue primarily through the sale of proprietary oral appliances, clinical diagnostic services, and practice management support offered to dentists and sleep clinicians. Its principal business segments include Medical Device Sales, Clinical Diagnostics, and Practice Management Services, which together support the end-to-end delivery of sleep apnea treatment. Revenue is largely derived from U.S.-based dental practices that are trained and certified to deliver Vivos therapies.

The company controls a portfolio of proprietary oral appliances and diagnostic protocols and operates through wholly owned subsidiaries including Vivos Integrated Practice Solutions, LLC and Vivos Medical Devices, LLC. A significant expansion of its operational capabilities occurred with the acquisition of Ortho-Tain, Inc., a long-established manufacturer of orthodontic appliances, which added in-house manufacturing and expanded product offerings. International operations exist but remain secondary to domestic activity.

Strategic Position & Investments

Vivos Therapeutics’ strategy centers on expanding awareness and adoption of non-invasive OSA treatment options, particularly among patients who are CPAP-intolerant. Growth initiatives have included vertical integration through acquisitions, expansion of its provider network, and investment in clinical validation of its treatment protocols. The acquisition of Ortho-Tain, Inc. represents the company’s most notable investment, providing manufacturing scale, supply chain control, and cross-selling opportunities.

The company has also invested in sleep diagnostic technologies and telemedicine-enabled care pathways to support physician oversight and regulatory compliance. Emerging areas of focus include broader sleep health screening, integration of digital monitoring tools, and expansion of payer reimbursement relationships. While management has articulated these strategic priorities in public disclosures, the pace and financial impact of these initiatives remain subject to market adoption and regulatory factors.

Geographic Footprint

Vivos Therapeutics is headquartered in Colorado, United States, and its primary operations and revenue generation occur within the United States. The company maintains a nationwide network of trained dental and medical providers, giving it broad domestic market coverage without a large physical clinic footprint. Manufacturing and administrative operations are also predominantly U.S.-based following its vertical integration strategy.

Internationally, Vivos has established limited market presence through provider relationships in Canada, Europe, and parts of Asia-Pacific, primarily via training programs and distributor arrangements. These international activities currently represent a smaller portion of overall operations but provide optionality for longer-term expansion as regulatory pathways and provider adoption mature.

Leadership & Governance

Vivos Therapeutics was founded by Kirk Huntsman, who continues to play a central role in shaping the company’s strategy and clinical philosophy. Leadership has emphasized an integrated, medically supervised approach to dental sleep medicine, with a focus on clinical evidence, provider education, and regulatory compliance. Governance and strategic direction are overseen by a board of directors with backgrounds in healthcare, medical devices, and public company management.

Key executives include:

• Kirk Huntsman – Chairman of the Board and Chief Executive Officer
• John Hopkinson – Chief Financial Officer
• Michael Davis – President

Public disclosures confirm the CEO and CFO roles; however, details regarding broader executive leadership and any recent role changes are limited in available public sources. Where titles or responsibilities are not consistently reported, data inconclusive based on available public sources.